Data imply that UGT2B17 represents a mechanism altering drug response in CLL through direct inactivation but would also involve additional mechanisms for drugs not inactivated by UGT2B17. The gene discussed is UGT2B17; the disease is B-cell chronic lymphocytic leukemia.